RE: BMJ says MHRA is reviewing Innova!14 Jun 2021 16:40
Like in who's moral compass did they think this was the right thing to do, when you are obviously cheating, to market a test that will then kill thousands with wrong results.
One thing is sure odx do not work in this manner. Slow and steady wins the race. After waiting and waiting no way am I leaving now. Mms can do one, cause the change is happening in our favour if you hold out imo...
So Recipe for tomorrows rise and beyond.13 Jun 2021 21:06
Lots of positve twitter action from all sorts. New faces on here talking good. Lack of derampers. Fundamentals changed with Innova. Technical charts singing above the mac gains. Decent Odx tweet to boot. All the ingredients or am I missing something...?
Of course orders would be the icing on the cake but wont happen now, too soon but I'd say the icing for this is urgently being prepped.
You think its a decent recipe to make this odx cake rise?
RE: Would not want to out over the weekend.11 Jun 2021 14:27
From the article 'In the UK, criticism of the Innova test has been fierce: the tests are not as effective as the gold-standard PCR tests' As cases are now on a new rise curve, its time that odx is fast tracked now to solve this crisis.
Er yes, this board has every parasitic down talking vermin possible. It's good to hear both reasoned sides, but those type talk it down constantly in a bad way for their own gains. Ignore those ones...
RE: Step Aside Innova,ODX Coming Through04 Jun 2021 00:54
Surely if a review is to take place then alternatives must be considered as part of this. We trump theirs in speed accuracy. So an order for Omega should be on the cards, its a flippin uk regulator who will be looking at omega a uk company, er hello?! If this doesn't make sense then I give up. If we dont have the capacity to fulfill the full order we should at least be in this next order. Tell me this makes sense. How could this not be the case now ?!
Prof Molloy, who has led the UK RTC for several months, says that critics of the speed of the programme need to take a “longer narrative”. Once the consortium is up and running at full capacity, the UK will be “more than 20 times magnified in our ability to produce lateral flow”, he says.
"Abbott had anticipated demand to remain high for its rapid, point-of-care tests—such as its card-based BinaxNow antigen diagnostic—thanks to continued coronavirus surveillance and screening programs meant to help people return to work or school."